Fairmont Banff Springs Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2003
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
HIV Vaccine Development: Immunological and Biological Challenges (X1)
Organizer(s) Richard A. Koup, David C. Montefiori and Brigitte Autran
March 29—April 4, 2003
Fairmont Banff Springs • Banff, AB Canada
Abstract Deadline: Dec 31, 2002
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 29, 2003
Sponsored by Wyeth Vaccines Research
Summary of Meeting:
Our efforts to curtail the worldwide spread of HIV infection are bolstered by the fact that we now have new information on the molecular and immunological basis of HIV infection. An intimate understanding of immunological control of HIV, and mechanisms by which HIV escapes that control, form the basis of developing novel strategies to prevent infection and disease. Many new vaccine products are now being tested in animal and human trials. Unlike other infections that have been prevented by vaccination, HIV specifically infects and destroys a key component of the immune response to intracellular pathogens. In addition, HIV is exquisitely capable of evading neutralizing antibody responses. All attempts to eliminate HIV from infected individuals have failed. The overall goal of this symposium will be to integrate the newest information on the molecular and cellular biology of HIV infection, the immune response to that infection, and the results of clinical trials of vaccine products. The program will identify the advances that have been made, and the challenges that remain, in developing a vaccine against HIV. The interaction between basic and applied scientists will foster accelerated research and development on HIV vaccines.
View Scholarships/Awards
Our efforts to curtail the worldwide spread of HIV infection are bolstered by the fact that we now have new information on the molecular and immunological basis of HIV infection. An intimate understanding of immunological control of HIV, and mechanisms by which HIV escapes that control, form the basis of developing novel strategies to prevent infection and disease. Many new vaccine products are now being tested in animal and human trials. Unlike other infections that have been prevented by vaccination, HIV specifically infects and destroys a key component of the immune response to intracellular pathogens. In addition, HIV is exquisitely capable of evading neutralizing antibody responses. All attempts to eliminate HIV from infected individuals have failed. The overall goal of this symposium will be to integrate the newest information on the molecular and cellular biology of HIV infection, the immune response to that infection, and the results of clinical trials of vaccine products. The program will identify the advances that have been made, and the challenges that remain, in developing a vaccine against HIV. The interaction between basic and applied scientists will foster accelerated research and development on HIV vaccines.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SATURDAY, MARCH 29
SUNDAY, MARCH 30
MONDAY, MARCH 31
TUESDAY, APRIL 1
WEDNESDAY, APRIL 2
THURSDAY, APRIL 3
FRIDAY, APRIL 4
Conference Program Print | View meeting in 12 hr (am/pm) time
SATURDAY, MARCH 29
19:30—21:30
Keynote Addresses (Joint)
*
Jay A. Levy,
University of California, San Francisco, USA
*
Richard A. Koup,
NIAID, National Institutes of Health, USA
Daniel Tarantola,
University of New South Wales, Australia
HIV/AIDS: Status of the Worldwide Epidemic
HIV/AIDS: Status of the Worldwide Epidemic
Richard B. Gaynor,
Neon Therapeutics, USA
Intracellular Events Involved in HIV-1 Replication
Intracellular Events Involved in HIV-1 Replication
08:00—11:00
Pioneer Lecture - Virology (Joint)
*
Mario Stevenson,
University of Miami, Leonard M. Miller School of Medicine, USA
08:00—11:00
Viral Diversity I (Joint)
Robert W. Doms,
University of Pennsylvania School of Medicine, USA
Virus Interaction at the Cell Surface
Virus Interaction at the Cell Surface
James E.K. Hildreth,
UC Davis College of Biological Sciences, USA
HIV-1, Lipid Rafts, and Primary Macrophages: Modeling HIV-1 as a Trojan Exosome
HIV-1, Lipid Rafts, and Primary Macrophages: Modeling HIV-1 as a Trojan Exosome
Cecilia Cheng-Mayer,
Aaron Diamond AIDS Research Center (ADARC), USA
Impact of HIV-1 Coreceptor Usage/Tropism on Viral Transmission, Persistence and Pathogenesis
Impact of HIV-1 Coreceptor Usage/Tropism on Viral Transmission, Persistence and Pathogenesis
17:00—19:00
Viral Diversity II (Joint)
*
Preston A. Marx,
Tulane National Primate Research Center, USA
*
Robert W. Coombs,
University of Washington, USA
Bette Tina Marie Korber,
Los Alamos National Laboratory, USA
Recombination: Now You See It, Now You Don't
Recombination: Now You See It, Now You Don't
Julie M. Overbaugh,
Fred Hutchinson Cancer Research Center, USA
The Role of Hormones and Viral Diversity in HIV-1 Pathogenesis.
The Role of Hormones and Viral Diversity in HIV-1 Pathogenesis.
Phyllis J. Kanki,
Harvard School of Public Health, USA
Pathogenesis of HIV Infections of Africa
Pathogenesis of HIV Infections of Africa
Vanessa M. Hirsch,
NIAID, National Institutes of Health, USA
Diversity of SIV: Relationship to Pathogenesis and Vaccine Development
Diversity of SIV: Relationship to Pathogenesis and Vaccine Development
08:00—11:00
Pioneer Lecture - Epidemiology
*
Jan Andersson,
Karolinska Institutet, Sweden
*
Richard W. Price,
University of California, San Francisco, USA
Harold W. Jaffe,
Centers for Disease Control and Prevention, USA
HIV Epidemiology: Then and Now
HIV Epidemiology: Then and Now
08:00—11:00
New Findings From Human Clinical Trials
Emilio A. Emini,
Bill and Melinda Gates Foundation, USA
Ongoing Development and Evaluation of a Potential HIV-1 Vaccine Using a Replication-Defective Adenoviral Vector
Ongoing Development and Evaluation of a Potential HIV-1 Vaccine Using a Replication-Defective Adenoviral Vector
Barney S. Graham,
NIAID, National Institutes of Health, USA
Update on Vaccine Research Center Clinical Trials of Candidate HIV Vaccines
Update on Vaccine Research Center Clinical Trials of Candidate HIV Vaccines
M. Juliana McElrath,
Fred Hutchinson Cancer Research Center, USA
Induction of Vaccine-Induced T Cell Responses and Their Role in HIV-1 Protection
Induction of Vaccine-Induced T Cell Responses and Their Role in HIV-1 Protection
Phillip W. Berman,
University of California, Santa Cruz, USA
Preliminary Results of the Phase III Efficacy Trial of AIDSVAX B/B
Preliminary Results of the Phase III Efficacy Trial of AIDSVAX B/B
08:00—11:00
HIV Pathogenesis I
Gene M. Shearer,
National Cancer Institute, National Institutes of Health, USA
HIV-1 Pathogenesis: Revisiting Discarded and Ignored Models
HIV-1 Pathogenesis: Revisiting Discarded and Ignored Models
Clayton A. Wiley,
University of Pittsburgh, USA
HIV and the Brain: What Have We Learned and Where Are We Going?
HIV and the Brain: What Have We Learned and Where Are We Going?
Donald P. Kotler,
St. Luke's Roosevelt Hospital Center, USA
HIV Pathogenesis in the Gastrointestinal Tract
HIV Pathogenesis in the Gastrointestinal Tract
Paul Klotman,
Mount Sinai Medical Center, USA
Renal Epithelium is a Reservoir for HIV-1 Replication
Renal Epithelium is a Reservoir for HIV-1 Replication
17:00—19:00
Pre-Clinical Leads in Non-Human Primates
Norman L. Letvin,
Beth Israel Deaconess Medical Center, USA
Defining Protective Immunity to SHIV in Non-Human Primates
Defining Protective Immunity to SHIV in Non-Human Primates
Ronald C. Desrosiers,
University of Miami Miller School of Medicine, USA
Single Cycle SIV as a Vaccine Approach for AIDS Factors that Influence Resistance to Antibody-Mediated Neutralization
Single Cycle SIV as a Vaccine Approach for AIDS Factors that Influence Resistance to Antibody-Mediated Neutralization
*
Harriet L. Robinson,
GeoVax Inc., USA
A Multiprotein DNA/MVA Vaccine for AIDS
A Multiprotein DNA/MVA Vaccine for AIDS
John K. Rose,
Yale University School of Medicine, USA
A Single VSV/SHIV Immunization Followed by One Heterologous MVA/SHIV Boost Results in Effective Control of Peak Virus Load After SHIV Challenge
A Single VSV/SHIV Immunization Followed by One Heterologous MVA/SHIV Boost Results in Effective Control of Peak Virus Load After SHIV Challenge
17:00—19:00
HIV Pathogenesis II
*
Anthony L. Cunningham,
Westmead Institute for Medical Research, Australia
*
Susan F. Plaeger,
NIAID, National Institutes of Health, HHS, USA
Henry Masur,
National Institutes of Health, USA
Opportunistic Infections in the Era of HAART
Opportunistic Infections in the Era of HAART
Patrick S. Moore,
University of Pittsburgh Cancer Institute, USA
KSHV and Its Designer Genes
KSHV and Its Designer Genes
Joel M. Palefsky,
University of California, San Francisco, USA
Cofactors: HPV infection
Cofactors: HPV infection
W. Henry Boom,
Case Western Reserve University, USA
M. tuberculosis: Hiding from the Host Implications for HIV-TB
M. tuberculosis: Hiding from the Host Implications for HIV-TB
20:00—22:00
Poster Session 2: The Virus, Antigen Presenting Cells, Innate and CD4+ T Cell Responses
08:00—11:00
Pioneer Lecture - Immunology (Joint)
*
Jack H. Nunberg†,
University of Montana, USA
Susan Zolla-Pazner,
Icahn School of Medicine at Mount Sinai, USA
Two Decades of Debate: The Role of Antibodies in HIV Immunity
Two Decades of Debate: The Role of Antibodies in HIV Immunity
08:00—11:00
Immune Responses in HIV Infection (Joint)
*
David C. Montefiori,
Duke University Medical Center, USA
Understanding the New Generation of Neutralizing Antibody Assays
Understanding the New Generation of Neutralizing Antibody Assays
John R. Mascola,
NIAID, National Institutes of Health, USA
Neutralizing Antibodies and Protective Immunity
Neutralizing Antibodies and Protective Immunity
Douglas F. Nixon,
Weill Cornell Medicine, USA
CD8 T cell Effector Subsets and HIV infection
CD8 T cell Effector Subsets and HIV infection
Mary Carrington,
NCI, National Institutes of Health, USA
The Multifaceted Effects of the HLA class I Loci on HIV-1 Disease
The Multifaceted Effects of the HLA class I Loci on HIV-1 Disease
17:00—19:00
The Envelope and Entry
*
Dan R. Littman,
HHMI/New York University School of Medicine, USA
Role of Dendritic Cells in HIV Entry and Host Immune Responses
Role of Dendritic Cells in HIV Entry and Host Immune Responses
Dennis R. Burton,
The Scripps Research Institute, USA
The Recognition of HIV-1 by Broadly Neutralizing Antibodies: Clues for Vaccine Design
The Recognition of HIV-1 by Broadly Neutralizing Antibodies: Clues for Vaccine Design
Peter D. Kwong,
NIAID, National Institutes of Health, USA
Application of Structural Biology to the Development of an HIV Vaccine
Application of Structural Biology to the Development of an HIV Vaccine
Cynthia A. Derdeyn,
Emory University, USA
Short Talk: Selective Heterosexual Transmission of Envelope-constrained, Neutralization-sensitive HIV-1
Short Talk: Selective Heterosexual Transmission of Envelope-constrained, Neutralization-sensitive HIV-1
17:00—19:00
Immune Responses (Innate) in HIV Infection II
*
Mario Clerici,
Dipartimento di Fisiologia Medico-Chirurgica e dei Trapianti, Italy
*
Carl W. Dieffenbach,
NIAID, National Institutes of Health, USA
Bruce A. Beutler,
University of Texas Southwestern Medical Center, USA
Forward Genetic Analysis of Innate Immunity
Forward Genetic Analysis of Innate Immunity
Christine A. Biron,
Brown University, USA
Interferon and NK Cell Responses to Viral Infections
Interferon and NK Cell Responses to Viral Infections
Jay A. Levy,
University of California, San Francisco, USA
Innate Immunity: Plasmacytoid Dendritic Cells and the CD8+ Cell Noncytotoxic Anti-HIV Response
Innate Immunity: Plasmacytoid Dendritic Cells and the CD8+ Cell Noncytotoxic Anti-HIV Response
Deborah J. Anderson,
Brigham and Women's Hospital, USA
Genital Tract Mucosal Immunity and HIV Infection
Genital Tract Mucosal Immunity and HIV Infection
20:00—22:00
Poster Session 3: Pre-Clinical/Clinical Evaluation of Vaccine Strategies
08:00—11:00
Pioneer Lecture - Clinical Approaches
*
Salvatore T. Butera,
Centers for Disease Control and Prevention, USA
*
Barbara Weiser,
New York State Department of Health, USA
Paul A. Volberding,
University of California, San Francisco, USA
Clinical Care
Clinical Care
08:00—11:00
Immunopathogenesis I
*
Rafi Ahmed,
Emory University School of Medicine, USA
Understanding Immunological Memory to Improve Vaccination Strategies"
Understanding Immunological Memory to Improve Vaccination Strategies"
Bruce D. Walker,
Ragon Institute of MGH, MIT and Harvard, USA
Immune Control and Immune Failure in HIV Infection
Immune Control and Immune Failure in HIV Infection
Giuseppe Pantaleo,
Centre Hospitalier Universitaire Vaudois, Switzerland
Protective CD4 and CD8 T Cell Responses in HIV-1 Infection
Protective CD4 and CD8 T Cell Responses in HIV-1 Infection
Genoveffa Franchini,
NCI, National Institutes of Health, USA
Modeling Immune Intervention Strategies for HIV-1 Infection of Humans in the Macaque Model
Modeling Immune Intervention Strategies for HIV-1 Infection of Humans in the Macaque Model
Olivier Schwartz,
Institut Pasteur, France
HIV and Dendritic Cells: Virus Spread and Antigen Presentation
HIV and Dendritic Cells: Virus Spread and Antigen Presentation
08:00—11:00
Antiviral Strategies I
Carl Grunfeld,
Veterans Affairs Medical Center, USA
The Role of Antiretroviral Drugs in Metabolic and Fat Distribution Changes of HIV Infection
The Role of Antiretroviral Drugs in Metabolic and Fat Distribution Changes of HIV Infection
Edward A. Berger,
NIAID, National Institutes of Health, USA
Immunotoxins to Target HIV Infected Cell Reservoirs
Immunotoxins to Target HIV Infected Cell Reservoirs
Flossie Wong-Staal,
ItherX Pharmaceuticals Inc., USA
Identification of Essential HIV Cellular Co-Factors through Genomic Approaches
Identification of Essential HIV Cellular Co-Factors through Genomic Approaches
Michael M. Lederman,
Case Western Reserve University, USA
Interleukin-2: A Determinant of Immune Competence in HIV disease? Will Administration Confer Clinical Benefit?
Interleukin-2: A Determinant of Immune Competence in HIV disease? Will Administration Confer Clinical Benefit?
14:30—16:30
Workshop: Recent Developments in Cytokine Augmentation of Vaccine-Induced Immunity
Karl J. Ljungberg,
Karolinska Institutet, Sweden
Priming with DNA and Recombinant GM-CSF Followed by Protein CpG-ODN Boost Induces Strong Anti HIV-1 Envelope Immune Responses in Mice
Priming with DNA and Recombinant GM-CSF Followed by Protein CpG-ODN Boost Induces Strong Anti HIV-1 Envelope Immune Responses in Mice
Dan H. Barouch,
Beth Israel Deaconess Medical Center, USA
Chemoattractant Plasmid Cytokines Augment DNA Vaccine-Elicited Immune Responses
Chemoattractant Plasmid Cytokines Augment DNA Vaccine-Elicited Immune Responses
*
John H. Eldridge,
Auro Vaccines, USA
Immunogenicity and Protective Capacity of a Cytokine-Enhanced DNA Prime/rVSV Boost Vaccination Regimen in Rhesus Macaques
Immunogenicity and Protective Capacity of a Cytokine-Enhanced DNA Prime/rVSV Boost Vaccination Regimen in Rhesus Macaques
David B. Weiner,
Wistar Institute, USA
Th1 Plasmid Cytokine Enhancement of RNA Optimized Plasmid DNA Vaccine Potency In Non Human Primates Suggests Attainment of a Critical Milestone In DNA Vaccine and Immune Therapy Development
Th1 Plasmid Cytokine Enhancement of RNA Optimized Plasmid DNA Vaccine Potency In Non Human Primates Suggests Attainment of a Critical Milestone In DNA Vaccine and Immune Therapy Development
17:00—19:00
Immunopathogenesis II
Robert F. Siliciano,
Johns Hopkins University School of Medicine, USA
Halting HIV Evolution
Halting HIV Evolution
*
Douglas D. Richman,
University of California, San Diego, USA
The Evolution and Neutralization Escape of HIV
The Evolution and Neutralization Escape of HIV
Daniel C. Douek,
NIAID, National Institutes of Health, USA
In Vivo distribution of HIV among T cell subsets
In Vivo distribution of HIV among T cell subsets
Louis J. Picker,
Oregon Health & Science University, USA
T Cell Dynamics in SIV Infection
T Cell Dynamics in SIV Infection
17:00—19:00
HIV Pathogenesis III
*
Ronald G. Collman,
University of Pennsylvania, USA
*
Loyda M. Meléndez,
University of Puerto Rico School of Medicine, USA
Crystal L. Mackall,
Stanford University, USA
Therapeutic Modulation of T Cell Homeostasis
Therapeutic Modulation of T Cell Homeostasis
Maria Prins,
Municipal Health Service, Netherlands
Gender Differences in HIV Infection
Gender Differences in HIV Infection
Keith R. Fowke,
University of Manitoba, Canada
Natural Immunity to HIV Infection
Natural Immunity to HIV Infection
20:00—22:00
Poster Session 4: HIV Tropism, Entry and Neutralizing Antibodies
08:00—11:00
Novel Approaches in Pre-Clinical and Clinical Development
Robert E. Johnston,
Global Vaccines, Inc., USA
Use of VEE to Stimulate Protective Immunity to HIV
Use of VEE to Stimulate Protective Immunity to HIV
*
Philip R. Johnson,
Children's Hospital of Philadelphia, USA
Pre-clinical Evaluation of a Novel HIV Vaccine Based on an Adeno-associated Virus Vector.
Pre-clinical Evaluation of a Novel HIV Vaccine Based on an Adeno-associated Virus Vector.
Jeffrey D. Lifson,
Leidos Biomedical Research, Inc., USA
Control of Pathogenic SIV Infection: Different Routes to the Same Goal
Control of Pathogenic SIV Infection: Different Routes to the Same Goal
Brigitte Autran,
Hôpital Pitié-Salpétrière, UPMC, France
Effect of Therapeutic Vaccination and STI on Immune Control of HIV
Effect of Therapeutic Vaccination and STI on Immune Control of HIV
08:00—11:00
HIV Pathogenesis IV
*
Peter Simmonds,
University of Edinburgh, UK
Klaus Strebel,
NIAID, National Institutes of Health, USA
HIV-1 Vif: A Multifunctional Adaptor Molecule
HIV-1 Vif: A Multifunctional Adaptor Molecule
Frederic D. Bushman,
University of Pennsylvania, USA
Twenty Years of Research on Retroviral Integration
Twenty Years of Research on Retroviral Integration
Tristram G. Parslow,
Emory University, USA
RNA Dimers as Templates for Viral and Cellular Reverse Transcription
RNA Dimers as Templates for Viral and Cellular Reverse Transcription
*
David Camerini,
University of California, Irvine, USA
James J. Goedert,
National Institutes of Health, USA
Roles of Hepatitis C virus (HCV) and GB virus C (GBV-C) in HIV Pathogenesis
Roles of Hepatitis C virus (HCV) and GB virus C (GBV-C) in HIV Pathogenesis
17:00—19:00
Late Breakers
*
Richard A. Koup,
NIAID, National Institutes of Health, USA
Daniel E. Kaufmann,
University of Montreal, Canada
Short Talk: Comprehensive Analysis of HIV-Specific CD4 Responses by IFN-Gamma Elispot in Early Chronic HIV-1 Infection Shows Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides
Short Talk: Comprehensive Analysis of HIV-Specific CD4 Responses by IFN-Gamma Elispot in Early Chronic HIV-1 Infection Shows Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides
Victor Appay,
INSERM U1135 - CIMI, France
Short Talk: Activation and Differentiation of HIV Non-Specific CD8+ T Cells During HIV-1 Infection
Short Talk: Activation and Differentiation of HIV Non-Specific CD8+ T Cells During HIV-1 Infection
Matthew R. Reynolds,
University of Wisconsin-Madison, USA
Short Talk: Viral Dissemination and Kinetics of Cytotoxic T-Lymphocyte Development in Mamu-A*01 Positive Macaques Infected with SIVmac239
Short Talk: Viral Dissemination and Kinetics of Cytotoxic T-Lymphocyte Development in Mamu-A*01 Positive Macaques Infected with SIVmac239
Ann Chahroudi,
Emory University School of Medicine, USA
Short Talk: Towards Better Strategies for Poxvirus-Based HIV Vaccines: Studies of the Cellular Tropism of Modified Vaccinia Ankara (MVA) and Vaccinia Virus (VV) in Primary Human Cells
Short Talk: Towards Better Strategies for Poxvirus-Based HIV Vaccines: Studies of the Cellular Tropism of Modified Vaccinia Ankara (MVA) and Vaccinia Virus (VV) in Primary Human Cells
Teunis B.H. Geijtenbeek,
University of Amsterdam, Netherlands
Short Talk: Mycobacteria Suppress Dendritic Cell Function: Effects on HIV-1 Infection
Short Talk: Mycobacteria Suppress Dendritic Cell Function: Effects on HIV-1 Infection
John P. Moore,
Weill Medical College of Cornell University, USA
Short Talk: Prevention of Virus Transmission to Macaque Monkeys by Vaginally Applied Entry Inhibitors
Short Talk: Prevention of Virus Transmission to Macaque Monkeys by Vaginally Applied Entry Inhibitors
Leonidas Stamatatos,
Fred Hutchinson Cancer Research Center, USA
Short Talk: Priming by Vaccination of HIV Envelope-Specific B-Cell Responses Allows for the Long-Term Control of SHIVSF162P4-Replication in Macaques
Short Talk: Priming by Vaccination of HIV Envelope-Specific B-Cell Responses Allows for the Long-Term Control of SHIVSF162P4-Replication in Macaques
Pascal Poignard,
IAVI Neutralizing Antibody Center at The Scripps Research Institute, USA
Short Talk: Stoichiometry of Neutralization of the Primary HIV-1 Isolate JR-CSF by the Anti-CD4 Binding Site Antibody b12
Short Talk: Stoichiometry of Neutralization of the Primary HIV-1 Isolate JR-CSF by the Anti-CD4 Binding Site Antibody b12
17:00—19:00
Late Breaking Observations and Conclusions
*
Alan L. Landay,
Rush Medical University, USA
Jerome A. Zack,
University of California, Los Angeles, USA
Strategies to Eliminate Latent HIV
Strategies to Eliminate Latent HIV
David M. Margolis,
University of North Carolina at Chapel Hill, USA
Derepression by DNA-binding Polyamides Allows Outgrowth of Human Immunodeficiency Type 1 from Resting CD4+ T Cells: Regulators of HIV Latency
Derepression by DNA-binding Polyamides Allows Outgrowth of Human Immunodeficiency Type 1 from Resting CD4+ T Cells: Regulators of HIV Latency
Thomas J. Hope,
Northwestern University, USA
Enhancement of HIV Infection by Dendritic Cells: Transfer of HIV to Target Cells Through an Infectious Synapse
Enhancement of HIV Infection by Dendritic Cells: Transfer of HIV to Target Cells Through an Infectious Synapse
Leonid Margolis,
NICHD, National Institutes of Health, USA
Viral Interactions in HIV-Infected Human Lymphoid Tissue
Viral Interactions in HIV-Infected Human Lymphoid Tissue
Joshua J. Anzinger,
NHLBI, National Institutes of Health, USA
Attachment Levels of HIV Differ between PBMC Donors In A CD4 Independent Manner
Attachment Levels of HIV Differ between PBMC Donors In A CD4 Independent Manner
Edward Barker,
Rush University Medical Center, USA
Inability of Natural Killer Cells to Destroy Autologous HIV-Infected Primary CD4+ T Cells
Inability of Natural Killer Cells to Destroy Autologous HIV-Infected Primary CD4+ T Cells
David J. Volsky,
Columbia University, St. Luke's Roosevelt Hospital Center, USA
Interaction of HIV with Astrocytes: A Case for a Direct Role of HIV in Neuropathogenesis
Interaction of HIV with Astrocytes: A Case for a Direct Role of HIV in Neuropathogenesis
Lishan Su,
University of North Carolina at Chapel Hill, USA
A Novel Genetic Approach to Inactivating Chemokine Receptors by a Modified HIV Protein
A Novel Genetic Approach to Inactivating Chemokine Receptors by a Modified HIV Protein
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
Boehringer Ingelheim (Canada) Ltd. |
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
